Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

CJ Bioscience announced today that it will present preclinical data on its novel drug candidate CJRB-201 at the European ...

“The preclinical results demonstrate ... Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy Volunteers Abstract Number ...

Preclinical studies in multiple animal models confirm significant improvements ... for the treatment of inflammatory bowel disease (IBD). The company has selected CJRB-201 as the next drug ...

Preclinical studies in multiple animal models confirm significant improvements ... conference in the field of inflammatory bowel disease (IBD), attracting gastroenterologists, researchers, and ...